- Conditions
- Wounds and Injuries
- Interventions
- Processed Amniotic Fluid, Standard of Care Wound Treatment Regimen
- Drug · Other
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 66
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Kidney Transplant Rejection
- Interventions
- Phenotypic Personalized Medicine Dosing, Standard of Care Dosing
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Stage IV Appendix Carcinoma AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
- Interventions
- Bevacizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Magnetic Resonance Imaging, Mitomycin, Questionnaire Administration
- Biological · Procedure · Drug + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 5
- States / cities
- Goodyear, Arizona • Duarte, California • Irvine, California + 2 more
- Conditions
- Small Cell Lung Cancer, Large Cell Neuroendocrine (NE) Tumors, Treatment Failure, Biomarkers / Blood, Biomarkers, Immunotherapy
- Interventions
- Carboplatin/Cisplatin -Etoposide - Atezolizumab
- Drug
- Lead sponsor
- Oncology Center of Biochemical Education And Research
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Infertility (IVF Patients), Infertility, Infertility Female
- Interventions
- CAPA-IVM, In-House CAPA-IVM Pre-Maturation Medium, Minimal-Stimulation OS-IVF
- Procedure · Device
- Lead sponsor
- New Hope Fertility Center
- Other
- Eligibility
- 18 Years to 38 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- MSGV1-PSCA-8T28Z, Fludarabine, Cyclophosphamide
- Biological · Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Child, Only, Disabilities Multiple, Medication Interaction, Medication Compliance, Medication Administered in Error
- Interventions
- Pediatric Medication Therapy Management (pMTM)
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 371 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Colon Cancer Screening
- Interventions
- Chewing Sugar-Free Gum During Bowel Preparation, Standard Bowel Prep (2L PEG-ELP), Standard Bowel Prep
- Behavioral · Other
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Towson, Maryland
- Conditions
- Diabetic Foot Ulcers, Venous Ulcers, Pressure Ulcers
- Interventions
- Autologous PRP Gel, Autologous PRP Injections, Autologous PRP Gel plus PRP Injections, Standard Wound Care
- Device · Procedure
- Lead sponsor
- Arteriocyte, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2014
- U.S. locations
- 6
- States / cities
- Bakersfield, California • Idaho Falls, Idaho • Englewood, New Jersey + 3 more
- Conditions
- Adenovirus
- Interventions
- Standard of Care, Brincidofovir
- Other · Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 2 Months to 25 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 11
- States / cities
- Los Angeles, California • San Francisco, California • Chicago, Illinois + 8 more
- Conditions
- Heart Failure
- Interventions
- Omecamtiv Mecarbil, Placebo, Standard of Care
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 8,256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 310
- States / cities
- Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 249 more
- Conditions
- Osteoporosis
- Interventions
- Standard Clinical Practice Regimen, Experimental Cyclic Regimen
- Drug
- Lead sponsor
- Health Research, Inc.
- Other
- Eligibility
- 45 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- West Haverstraw, New York
- Conditions
- Leukemia, Myeloma, Myeloproliferative Diseases
- Interventions
- Fludarabine, Melphalan, Alemtuzumab, Stem Cell infusion, Tacrolimus, Mini Methotrexate, G-CSF, Donor Lymphocyte Infusion (DLI), AP1903, Methylprednisolone, Questionnaire
- Drug · Procedure · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
- Interventions
- Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
- Biological · Other · Drug
- Lead sponsor
- Beat AML, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2032
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
- Conditions
- Stroke
- Interventions
- Isometric Progressive Resistance Oropharyngeal Therapy, Compensatory approaches
- Device · Behavioral
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 21 Years to 95 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Chronic Pain
- Interventions
- Cognitive Behavioral Therapy (CBT), Exercise Counseling and tele-EnhanceFitness, Care Coordination, Standard Clinical Practice Regimen
- Behavioral · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Inflammatory Bowel Disease
- Interventions
- Filgotinib, Placebo, Standard of Care
- Drug
- Lead sponsor
- Lakefront Biotherapeutics NV
- Industry
- Eligibility
- 21 Years to 65 Years · Male only
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 10
- States / cities
- San Diego, California • Lakewood Rch, Florida • Miami, Florida + 7 more
- Conditions
- Smoking Cessation
- Interventions
- UP-ST Therapy, Standard Therapy, Nicotine Patch
- Behavioral · Device
- Lead sponsor
- University of Houston
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Heart Failure, Heart Failure Acute, Acute Cardiac Pulmonary Edema, Acute Cardiac Failure
- Interventions
- LUS-guided strategy-of-care, Usual Care, Intravenous Loop Diuretic, Vasodilator, Non invasive Ventilation (NIV)
- Other · Drug · Device
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 6
- States / cities
- Indianapolis, Indiana • Detroit, Michigan • Cleveland, Ohio + 2 more
- Conditions
- Transcatheter Aortic Valve Replacement (TAVR), Aortic Valve Stenosis
- Interventions
- Propofol, Dexmedetomidine, Midazolam, Fentanyl
- Drug
- Lead sponsor
- David Lyubashevsky
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Glenview, Illinois
- Conditions
- Heart Failure, Diabetes Mellitus
- Interventions
- Libre 2 rt-CGM, POC BG + Blinded CGM
- Device · Diagnostic Test
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Acute Peripheral Arterial Occlusion
- Interventions
- Plasmin, Plasminogen Activator, Placebo
- Biological · Other
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 2
- States / cities
- Buffalo, New York • Cleveland, Ohio
- Conditions
- Anterior Knee Pain Syndrome
- Interventions
- Knee Isometric Program (KIP)
- Behavioral
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer
- Interventions
- palbociclib, trastuzumab, pertuzumab, letrozole, Anastrozole, Exemestane, Fulvestrant
- Drug
- Lead sponsor
- Alliance Foundation Trials, LLC.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 518 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 35
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Clearwater, Florida + 30 more